10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Anti-PD-L1 (Extracellular region) M080 Antibody

Catalog # AN1897

Product Information

Application	WB, ICC, IP
Primary Accession	Q9NZQ7
Host	Mouse
Clonality	Mouse Monoclonal
Isotype	IgG1
Clone Names	M080
Calculated MW	33275

Additional Information

Gene ID	29126
Other Names	Programmed cell death 1 ligand 1, PD-L1, PDCD1 ligand 1, Programmed death ligand 1, hPD-L1, B7 homolog 1, B7-H1, CD274, B7H1, PDCD1L1, PDCD1LG1, PDL1
Dilution	WB~~1:1000 ICC~~N/A IP~~N/A
Storage	Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions	Anti-PD-L1 (Extracellular region) M080 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.
Shipping	Blue Ice

Background

Programmed cell death 1 ligand 1 (PD-L1, B7-H1, CD274) is a member of the B7 family of cell surface ligands that regulate T cell activation and immune responses. The B7 family members have conserved regions that include extracellular IgV and IgC domains, and a short cytoplasmic region. Research studies demonstrate that PD-L1 is expressed in several tumor types, including melanoma, ovary, colon, lung, breast, and renal cell carcinomas. PD-L1 plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, which promotes tumor survival. The blockage of the PD1/PD-L1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy. Several therapies that target PD1/PD-L1 pathways are currently in use or in clinical trials

Images

Western blot of human recombinant PD-L1 extracellular



region (40 kDa; lanes 1 & 3) and endogenous PD-L1 in human lung (lanes 2 & 4). The blot was probed with mouse monoclonals anti-PD-L1 (PM0511) at 1:500 (lanes 1 & 2) and anti-PD-L1 (AN1897) at 1:250 (lanes 3 & 4).



Immunocytochemical labeling of PD-L1 in aldehyde fixed human MDA-MB-231 carcinoma cells untreated (A) or treated with 100 ng/ml IFNγ for 48 hrs (B). The cells were labeled with mouse monoclonal anti-PD-L1 (AN1897). The antibody was detected using goat anti-mouse DyLight® 594.



Representative Standard Curve using mouse monoclonal anti-PD-L1 (AN1897) for ELISA capture of human recombinant PD-L1 extracellular region with a His-tag. Captured protein was detected by suitable anti-His-tag antibody followed by appropriate secondary antibody HRP conjugate.